OakChart

Relay Therapeutics Inc

RLAYHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

19.72-0.22 (-1.10%)
2026-11-12 01:44 CET
Market cap
4,357.31 USD m
Revenue, TTM
10.35 USD m
Net income, TTM
-293.63 USD m
Free cash flow, TTM
-214.02 USD m
EPS diluted, TTM
-1.51
P/E
-
Compare

Price

RLAY against its 20, 50 and 200-day averages
2050200beatearnings
10.0015.0020.008.9M17.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RLAYclose 19.7220-day 18.3550-day 18.40200-day 15.4319.7252w high

7.3% under the 52-week high of 21.27 on 19 Aug 2026. 52-week low 5.95 on 11 Nov 2025. Last 15 sessions, 26.9% high to low

Volume 0.67× normal · the line is the 50-bar volume average

Profile

RLAY
52-week range, 90% of the way up
5.9521.27

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

IndexRUT
Employees192
IPOJul 16, 2020
Beta1.72
ATR, 14d1.15
Rel volume0.67
Short float25.21%
Insider own21.67%
Inst own98.75%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.36B
Enterprise Value3.54B
Income-293.63M
Sales10.35M
Book/sh3.73
Cash/sh3.84
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees192
IPOJul 16, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S421.00
P/B5.29
P/C5.13
P/FCF-
EV/EBITDA-
EV/Sales341.61
Quick Ratio14.62
Current Ratio14.62
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.51
EPS next Y-1.58
EPS next Q-0.35
EPS this Y3.51%
EPS next Y-1.90%
EPS next 5Y0.73%
EPS past 3/5Y14.61% 8.85%
Sales past 3/5Y123.20% -28.58%
EPS Y/Y TTM13.76%
Sales Y/Y TTM23.86%
EPS Q/Q13.28%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.6.75% -16.70%

Ownership

Insider Own21.67%
Insider Trans-12.18%
Inst Own98.75%
Inst Trans18.05%
ROA-37.37%
ROE-41.16%
ROIC-34.85%
Gross Margin83.16%
Oper. Margin-3094.58%
Profit Margin-2837.03%
SMA207.49%
SMA507.17%
SMA20027.77%
Trades-

Technical

Shs Outstand219.50M
Shs Float173.08M
Short Float25.21%
Short Ratio15.11
Short Interest43.63M
52W High21.27 -7.29%
52W Low5.95 231.43%
Volatility9.42% 6.33%
ATR (14)1.15
RSI (14)56.92
Beta1.72
Rel Volume0.67
Avg Volume2.89M
Volume1,932,271

Performance

Perf Week9.37%
Perf Month13.59%
Perf Quarter-1.05%
Perf Half Y49.17%
Perf YTD133.10%
Perf Year213.51%
Perf 3Y157.44%
Perf 5Y-44.76%
Perf 10Y-
Recom1.08
Target Price28.25
Prev Close19.94
Price19.72
Change %-1.10%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 16, 2026InitiatedCCanaccord GenuityBuy$29+47.1%
Jul 08, 2026InitiatedJJP MorganOverweight$28+42.0%
Jan 26, 2026UpgradeOOppenheimerPerform → Outperform$14-29.0%
Dec 12, 2025UpgradeWWells FargoEqual Weight → Overweight$13-34.1%
Sep 04, 2025ResumedGGuggenheimBuy$15-23.9%
Apr 17, 2025InitiatedWWells FargoEqual Weight$4-79.7%
Sep 10, 2024UpgradeJJefferiesHold → Buy$10.60 → $16-18.9%
Sep 10, 2024ResumedGGoldmanBuy$20+1.4%
Sep 10, 2024DowngradeOOppenheimerOutperform → Perform
May 10, 2024UpgradeBBarclaysEqual Weight → Overweight$15-23.9%

Peers

Mkt cap
TickerCompanyMkt cap
CELCCelcuity Inc3.16B
OLMAOlema Pharmaceuticals Inc703.48M
ARVNArvinas Inc452.51M
PVLAPalvella Therapeutics Inc2.40B
ERASErasca Inc5.88B
IDYAIdeaya Biosciences Inc3.16B
TNGXTango Therapeutics Inc4.36B
LLYLilly(Eli) & Co1352.12B
NVSNovartis AG ADR293.47B
AZNAstrazeneca plc287.66B

Insider trading

latest 14 of 52
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Rahmer PeterSee remarksOct 28 '26Sale18.6275314,021222,904Oct 30 04:18 PM
Bergstrom Donald APresident, R&DOct 28 '26Sale18.622,25241,932396,878Oct 30 04:15 PM
Catinazzo ThomasChief Financial OfficerOct 28 '26Sale18.621,46927,353103,665Oct 30 04:14 PM
Patel SanjivPresident and CEOOct 07 '26Sale18.1048,199872,402471,301Oct 08 05:29 PM
Catinazzo ThomasChief Financial OfficerOct 06 '26Sale18.5917,717329,322105,134Oct 08 05:29 PM
SANJIV PATELDirectorOct 07 '26Proposed Sale18.7496,4011,806,555Oct 07 04:35 PM
THOMAS CATINAZZOOfficerOct 06 '26Proposed Sale19.3993,1531,806,237Oct 06 04:21 PM
Bergstrom Donald APresident, R&DSep 08 '26Sale18.978,530161,814399,130Sep 09 04:17 PM
Catinazzo ThomasChief Financial OfficerSep 08 '26Sale18.9417,717335,560122,851Sep 09 04:15 PM
Patel SanjivPresident and CEOSep 08 '26Sale18.9448,199912,889519,500Sep 09 04:12 PM
Rahmer PeterSee remarksAug 26 '26Sale20.034,50890,295223,657Aug 28 04:43 PM
SVF Pauling (Cayman) Ltd10% OwnerAug 25 '26Sale19.406,000,000116,400,00021,904,963Aug 28 09:01 AM
PETER RAHMEROfficerAug 26 '26Proposed Sale20.5750,0001,028,500Aug 26 04:15 PM
SVF Pauling (Cayman) LtdStockholderAug 25 '26Proposed Sale20.576,000,000123,420,000Aug 25 07:43 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.62B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200
  • Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire) -5.71%
  • Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November (GlobeNewswire) -5.83%
  • Relay Therapeutics Heads Into Q3 With A Rerated Stock And Burn Discipline In Focus (Earnings Whispers)
  • Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 (GlobeNewswire)
  • What Could Go Wrong With Recursion Pharmaceuticals Stock? (Trefis)
  • Raymond James Updates Healthcare Top Picks for October (Investing.com)
  • Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire)
  • Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
  • This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion (Investor's Business Daily) -5.01%
  • Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire)
  • Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 (GlobeNewswire) +5.88%
  • An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers (PR Newswire)
  • Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June (GlobeNewswire)
  • Relay Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +7.87%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.370-0.397-0.3711.351.6213
2026Q22026-08-06-0.410-0.391-0.4130.350.9614
2026Q12026-05-05-0.410-0.363-0.4083.005.5813
2025Q42026-02-26-0.320-0.405-0.3177.004.9711
2025Q32025-11-06-0.430-0.415-0.4300.000.1611
2025Q22025-08-07-0.410-0.492-0.4110.700.0811
2025Q12025-05-05-0.460-0.489-0.4557.680.0111
2024Q42025-02-26-0.450-0.561-0.4540.006.0812
2024Q32024-11-06-0.630-0.772-0.6280.000.0912
2024Q22024-08-06-0.690-0.733-0.6940.010.0911
2024Q12024-05-02-0.620-0.727-0.62210.000.1211
2023Q42024-02-22-0.670-0.718-0.6690.000.5812
2023Q32023-11-02-0.540-0.825-0.53825.200.3712
2023Q22023-08-08-0.810-0.816-0.8100.120.7411
2023Q12023-05-04-0.780-0.691-0.7770.230.1311
2022Q42023-02-23-0.560-0.702-0.5580.250.279

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-5.400-4.810-2.56082.6538.75
2021FY-3.820-3.688-3.8253.036.41
2022FY-2.590-2.742-2.5881.384.46
2023FY-2.790-2.828-2.79025.5524.30
2024FY-2.360-2.508-2.36410.0115.08
2025FY-1.610-1.732-1.61015.3612.81
2026FY--1.554--9.82
2027FY--1.583--11.55
2028FY--1.585--20.32
2029FY--1.090--178.62
2030FY--0.275--463.44

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1011215.910.0027.20
2026Q4S2026-11-0611225.910.0027.20
2026Q4S2026-11-0511135.880.0027.20
2026Q4S2026-11-0411017.100.0027.20
2026Q4S2026-10-2711017.100.0027.20
2026Q4S2026-10-2111027.100.0027.20
2026Q4S2026-08-2711037.100.0027.20
2026Q4S2026-08-1311027.140.0027.20
2026Q4S2026-08-0711017.380.0027.20
2026Q4S2026-08-0511007.450.0027.20
2026Q4S2026-08-0311107.450.0027.20
2026Q4S2026-07-2011207.450.0027.20
2026Q4S2026-07-0711317.450.0027.20
2026Q4S2026-06-1110317.900.0027.20

Estimate history

EPS, annual-0.543-0.838-2.56-3.825-2.588-2.79-2.364-1.611-1.5097
Period20182019202020212022202320242025TTM
EPS, quarterly-0.628-0.454-0.455-0.411-0.43-0.317-0.408-0.413-0.373
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0082.6543.0291.38125.54610.00715.35510.35
Period20182019202020212022202320242025TTM
Sales, quarterly007.6790.6770730.350
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual89.87689.87689.907108.21121.112127.462167.756173.869219.502
Period20182019202020212022202320242025MRQ
Shares, quarterly166.887167.756170.484171.692172.631173.869189.209218.531219.502
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue10.3515.3610.0125.551.383.0382.650.000.00
Cost of Goods Sold Incl. D&A1.743.565.465.274.133.923.552.852.15
Gross Profit8.6111.804.5420.28-2.75-0.9079.11-2.85-2.15
Selling, General and Administrative Excl. Other328.90314.54390.22399.70308.20225.21134.9081.2047.73
Research and Development279.60261.38319.09330.02246.35169.5396.9767.9039.33
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-320.29-302.74-385.67-379.42-310.95-226.11-55.80-84.05-49.89
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.00-13.21-6.42-11.68138.590.000.000.00
Net Income Before Taxes-293.63-276.48-337.71-341.97-290.51-363.87-52.41-75.31-48.78
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-293.63-276.48-337.71-341.97-290.51-363.87-52.41-75.31-48.78
Net Income From Continuing Operations-293.63-276.48-337.71-341.97-290.51-363.87-52.41-75.31-48.78
Net Income-293.63-276.48-337.71-341.97-290.51-363.87-230.20-75.31-48.78
EPS (Recurring)-1.34-1.61-2.43-2.83-2.66-2.80-2.56-0.84-0.54
EPS (Basic, Before Extraordinaries)-1.51-1.61-2.36-2.79-2.59-3.82-2.56-0.84-0.54
EPS (Diluted)-1.51-1.61-2.36-2.79-2.59-3.82-2.56-0.84-0.54
EBITDA-318.55-299.18-380.21-374.15-306.82-222.18-52.25-81.20-47.73
Non-Operating Income (Expense)26.6626.2634.7631.038.770.833.388.741.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense42.9062.4294.1486.0356.1448.4531.964.462.89
Price To Sales Ratio382.2094.5458.8252.831,214.17964.5645.21--
Gross Margin83.1676.8345.4079.37-199.06-29.5895.71--
Operating Margin-3,094.58-1,971.59-3,854.04-1,485.25-22,516.44-7,464.74-67.51--
Net Margin-2,837.03-1,800.58-3,374.72-1,338.66-21,036.13-12,012.94-278.51--
Shares Outstanding219.50173.87167.76127.46121.11108.2189.9189.8889.88
Market Capitalization4,357.314,405.92689.621,357.191,806.172,846.673,739.773,954.83-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.353.007.000.000.687.680.00
Cost of Goods Sold Incl. D&A0.280.360.500.600.751.001.211.33
Gross Profit-0.28-0.012.506.40-0.75-0.336.47-1.33
Selling, General and Administrative Excl. Other89.9790.8181.0967.0379.6476.5291.3483.64
Research and Development77.1476.4870.5655.4168.2663.9073.8168.08
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-90.25-90.82-78.59-60.63-80.39-76.85-84.87-84.98
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-81.75-83.71-73.29-54.89-74.15-70.38-77.06-76.00
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-81.75-83.71-73.29-54.89-74.15-70.38-77.06-76.00
Net Income From Continuing Operations-81.75-83.71-73.29-54.89-74.15-70.38-77.06-76.00
Net Income-81.75-83.71-73.29-54.89-74.15-70.38-77.06-76.00
EPS (Recurring)-0.37-0.41-0.41-0.32-0.43-0.41-0.46-0.45
EPS (Basic, Before Extraordinaries)-0.37-0.41-0.41-0.32-0.43-0.41-0.46-0.45
EPS (Diluted)-0.37-0.41-0.41-0.32-0.43-0.41-0.46-0.45
EBITDA-89.97-90.46-78.09-60.03-79.64-75.84-83.66-83.64
Non-Operating Income (Expense)8.507.125.305.746.246.477.808.97
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.129.1810.5413.0715.5314.5019.3217.64
Price To Sales Ratio382.20366.70167.6095.53107.6970.9257.7468.89
Gross Margin--2.8683.2091.44--48.0184.27-
Operating Margin--25,949.71-2,619.67-866.14--11,351.11-1,105.21-
Net Margin--23,916.29-2,443.03-784.14--10,395.13-1,003.58-
Shares Outstanding219.50218.53189.21173.87172.63171.69170.48167.76
Market Capitalization4,357.314,077.661,778.321,466.30899.99593.20444.15689.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments554.52781.32750.09998.92958.07678.06355.82421.50
Short Term Receivables0.000.000.005.224.9482.650.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets23.7627.8820.0215.3713.239.384.722.60
Total Current Assets578.28809.20770.101,019.50976.24770.10360.54424.10
Net Property, Plant & Equipment41.7257.6768.8775.3927.3228.8331.653.63
Total Investments and Advances1.342.122.712.582.580.880.880.88
Intangible Assets0.002.302.302.302.30-0.000.00
Other Assets0.000.000.000.000.000.020.000.00
Total Assets621.33871.30843.981,099.771,008.44799.83393.07428.61
Short Term Debt Incl. Current Port. of LT Debt3.775.734.964.281.841.521.250.18
Accounts Payable7.7114.109.2110.588.286.356.994.71
Other Current Liabilities14.1130.9116.0948.8514.205.763.751.98
Total Current Liabilities25.5850.7330.2763.7124.3213.6311.996.87
Long Term Debt28.6942.7748.5053.4721.0622.9023.580.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.0013.2132.3865.260.000.160.55
Total Liabilities54.2793.5091.98149.55110.6436.5435.737.42
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00537.78532.12
Common Equity567.06777.79752.00950.22897.81763.29-180.44-110.93
Total Shareholders Equity567.06777.79752.00950.22897.81763.29357.34421.19
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity567.06777.79752.00950.22897.81763.29357.34421.19
Total Liabilities & Stockholders Equity621.33871.30843.981,099.771,008.44799.83393.07428.61
Book Value Per Share3.264.645.907.858.308.49-2.01-1.23
Tangible Book Value Per Share3.264.625.887.838.288.49-2.01-1.23
Full-Time Employees192261323327245159122-
Price to Book Ratio5.340.821.741.813.704.905.53-
Return on Assets-37.05-39.38-35.19-27.56-40.25-8.79-18.33-
Return on Equity-41.12-44.15-40.18-31.44-43.81-9.35-19.35-
Return on Invested Capital-46.41-41.16-42.72-28.94-39.60-6.67-19.77-11.58
Quick Ratio22.6115.9525.4416.0040.1456.4930.0861.78
Current Ratio22.6115.9525.4416.0040.1456.4930.0861.78

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-293.63-276.48-337.71-341.97-290.51-363.87-52.41-75.31-48.78
Depreciation1.743.565.465.274.133.923.552.852.15
Other Funds (Non Cash)42.7760.7768.5268.8545.64188.2031.542.022.90
Funds from Operations-249.12-212.15-263.73-267.86-240.74-171.75-17.32-70.44-43.73
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital35.10-23.3114.62-32.4611.2597.34-85.174.31-0.40
Cash from Operating Activities-214.02-235.46-249.11-300.32-229.49-74.41-102.49-66.13-44.13
Capital Expenditures-0.00-0.41-2.02-4.13-9.06-3.47-1.93-8.00-1.69
Net Assets From Acquisitions0.000.000.000.000.00-25.300.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.020.01
Purchase or Sale of Investments-222.29193.21-39.07261.76-179.68-450.7483.60-311.040.00
Purchase of Investments-677.73-122.97-650.63-385.54-535.42-980.66-266.45-553.520.00
Sale Or Maturity of Investments455.44316.18611.56647.30355.74529.92350.06242.470.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-222.29192.80-41.08257.63-188.75-479.5181.67-319.02-1.68
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock467.871.60270.1534.75289.91388.09426.510.610.72
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.08
Sale of Common Pref Stock467.871.60270.1534.75289.91388.09426.510.610.80
Proceedsfrom Stock Options456.030.00265.8930.28286.43383.35425.290.000.80
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.004.99394.25
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities467.871.60270.1534.75289.91388.09426.515.61394.97
Net Change in Cash31.56-41.05-20.04-7.93-128.32-165.83405.69-379.55349.16
Free Cash Flow-214.02-235.87-251.12-304.44-238.55-77.88-104.42-74.14-45.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments848.64910.93642.07554.52596.43656.77
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets16.2117.1516.4023.7627.5823.62
Total Current Assets864.85928.08658.46578.28624.01680.39
Net Property, Plant & Equipment30.8938.0439.8141.7243.7346.19
Total Investments and Advances1.201.341.341.342.262.26
Intangible Assets4.750.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets901.69967.46699.61621.33670.00728.84
Short Term Debt Incl. Current Port. of LT Debt3.494.013.893.773.643.52
Accounts Payable9.1911.464.107.712.755.18
Other Current Liabilities46.4835.3321.7614.1126.2123.82
Total Current Liabilities59.1550.8029.7525.5832.6032.52
Long Term Debt23.5426.6427.6828.6929.6930.66
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities82.7077.4557.4354.2762.2963.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity819.00890.01642.18567.06607.71665.66
Total Shareholders Equity819.00890.01642.18567.06607.71665.66
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity819.00890.01642.18567.06607.71665.66
Total Liabilities & Stockholders Equity901.69967.46699.61621.33670.00728.84
Book Value Per Share3.734.073.393.263.523.88
Tangible Book Value Per Share3.714.073.393.263.523.88
Full-Time Employees-202193192188-
Price to Book Ratio5.295.513.052.401.350.82
Return on Assets-37.37-33.72-36.39-37.05-37.20-41.50
Return on Equity-41.16-36.77-40.01-41.12-41.14-46.24
Return on Invested Capital-9.70-9.13-10.94-9.21-11.63-10.11
Quick Ratio14.6218.2722.1322.6119.1420.92
Current Ratio14.6218.2722.1322.6119.1420.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-81.75-83.71-73.29-54.89-74.15-70.38
Depreciation0.280.360.500.600.751.00
Other Funds (Non Cash)12.218.559.7612.2414.7816.02
Funds from Operations-69.25-74.79-63.03-42.05-58.62-53.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.3220.6811.92-2.82-3.50-1.91
Cash from Operating Activities-63.93-54.11-51.11-44.87-62.12-55.26
Capital Expenditures0.000.000.00-0.000.00-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments62.37-353.0332.9035.4639.7275.17
Purchase of Investments-121.51-471.33-50.90-34.00-58.08-8.93
Sale Or Maturity of Investments183.88118.3083.8069.4697.8084.10
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities62.37-353.0332.9035.4639.7375.15
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.42323.74138.780.930.020.65
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.42323.74138.780.930.020.65
Proceedsfrom Stock Options0.00318.94137.090.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.42323.74138.780.930.020.65
Net Change in Cash2.86-83.40120.57-8.47-22.3820.54
Free Cash Flow-63.93-54.11-51.11-44.87-62.12-55.29

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 10.01M 2025: 15.36M
United States2024: 10.01M 2025: 15.36M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.21%43.6M173.1M2.74M
2026-10-1525.65%44.0M171.7M2.78M
2026-09-3027.24%46.7M171.6M2.85M
2026-09-1525.93%44.5M171.6M3.19M
2026-08-3125.43%43.6M171.3M3.32M
2026-08-1425.03%41.4M165.2M3.83M
2026-07-3123.47%40.3M171.5M3.98M
2026-07-1524.95%42.6M170.6M4.15M
2026-06-3026.25%43.0M164.0M4.31M
2026-06-1523.27%38.1M163.8M3.68M
2026-05-2921.10%34.4M163.0M3.54M
2026-05-1520.12%28.8M143.3M2.97M
2026-04-3019.23%27.4M142.6M2.95M
2026-04-1520.30%27.0M133.0M2.85M
2026-03-3116.68%21.9M131.5M2.43M
2026-03-1315.09%19.8M131.5M2.46M
2026-02-2714.78%19.4M131.5M2.25M
2026-02-1315.60%19.9M127.5M2.28M
2026-01-3018.38%24.0M130.7M2.24M
2026-01-1517.16%22.4M130.5M2.18M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10.007.7012.500.007.6190.000.000.916-0.1110.005
call11.006.7011.500.006.8500.000.000.905-0.1090.005
call12.005.7010.500.006.1630.000.000.892-0.1050.006
call13.004.809.500.005.5400.000.000.878-0.1010.006
call14.003.808.300.004.8510.000.000.860-0.0970.007
call15.002.807.500.004.4350.000.000.840-0.0920.007
call16.001.806.500.003.9330.000.000.813-0.0850.008
call17.001.005.502.093.5485100.000.778-0.0780.009
call18.000.103.001.701.7272470.000.669-0.2080.011
call19.000.252.851.802.0601640.000.625-0.2020.012
call20.000.351.800.951.5682040.000.563-0.1710.012
call21.000.052.000.751.8891500.000.494-0.1510.012
call22.000.051.050.501.5332,1200.000.369-0.1010.012
call23.000.001.650.201.76380.000.000.337-0.1120.011
call24.000.002.250.151.9701220.000.314-0.1220.011
call25.000.002.400.312.15985.000.000.296-0.1300.011
call26.000.003.800.112.3321500.000.282-0.1370.010
call27.000.003.800.052.44452.000.000.263-0.1390.010
put10.000.003.800.004.1310.000.00-0.084-0.1100.005
put11.000.003.800.003.6670.000.00-0.095-0.1070.005
put12.000.003.800.053.2433.000.00-0.108-0.1040.006
put13.000.003.800.102.8512920.00-0.122-0.1000.006
put14.000.003.800.202.4849.000.00-0.140-0.0950.007
put15.000.003.800.102.1365950.00-0.160-0.0900.007
put16.000.003.700.051.80245.001.00-0.187-0.0840.008
put17.000.000.650.211.4762130.00-0.222-0.0760.009
put18.000.003.100.803.38121.000.00-0.331-0.2060.011
put19.000.053.802.753.5069.000.00-0.375-0.2000.012
put20.000.054.600.003.6770.000.00-0.437-0.1690.012
put21.000.954.900.003.3980.000.00-0.506-0.1480.012
put22.000.104.900.002.8550.000.00-0.631-0.0990.012
put23.001.005.500.002.7750.000.00-0.663-0.1100.011
put24.002.006.506.283.0001.000.00-0.686-0.1190.011
put25.003.007.400.003.1210.000.00-0.704-0.1270.011
put26.003.808.408.203.3101.000.00-0.718-0.1340.010
put27.004.709.509.103.5721.000.00-0.737-0.1360.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-04SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-07144Filing for proposed sale of securities under Rule 144.SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-06424B5SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06SCHEDULE 13GSEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-07-31144Filing for proposed sale of securities under Rule 144.SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-21144Filing for proposed sale of securities under Rule 144.SEC
2026-07-20144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.29M5
2026-09001.41M3
2026-0800117.82M4
2026-07001.52M6
2026-06005.71M3
2026-0500227.84K1
2026-0400305.05K5
2026-0300178.23K1
2026-020000
2026-0100724.35K7
2025-120000
2025-1100434.51K1

Institutional holders

Manager% owned
SB INVESTMENT ADVISERS12.80%
FMR LLC11.06%
Casdin Capital, LLC7.36%
BlackRock, Inc.7.01%
PERCEPTIVE ADVISORS LLC6.47%
Commodore Capital LP5.51%
STATE STREET CORP4.65%
VANGUARD CAPITAL MANAGEMENT LLC4.11%
PRICE T ROWE ASSOCIATES INC /MD/3.54%
Nextech Invest Ltd.3.11%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.12%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.89%
iShares Russell 2000 ETF1.91%
Select Health Care Portfolio0.95%
VANGUARD EXTENDED MARKET INDEX FUND0.89%
Strategic Advisers Fidelity U.S. Total Stock Fund0.89%
Fidelity Small Cap Growth Fund0.88%
Fidelity Advisor Biotechnology Fund0.85%
T. Rowe Price Health Sciences Fund, Inc.0.84%
Fidelity Small Cap Index Fund0.81%

OakChart. RLAY. Cached 15 minutes.